Spontaneous coronary artery dissection (SCAD) is gaining recognition as an important cause of myocardial infarction, especially in young women. There has been a surge in the diagnosis of SCAD in recent years, presumably due to an increased use of coronary angiography, and the clinical availability and application of high-resolution intracoronary imaging. The improved recognition and diagnosis, together with increased publications and attention through social media, have considerably raised awareness of this condition, which was once believed to be very rare. Recent publications of moderate to large contemporary case series have helped elucidate the early natural history, presenting characteristics (clinical and angiographic), underlying etiology, management, and cardiovascular outcomes with this condition, thus providing observations and important clinical insights of value to clinicians managing this challenging and perplexing patient cohort. The aim of our review is to provide a comprehensive contemporary update of SCAD to aid health care professionals in managing these patients in both the acute and chronic settings. (J Am Coll Cardiol 2016;68:297-312) 
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DEFINITION OF SCAD
SCAD is defined as a spontaneous separation of the coronary artery wall that is not iatrogenic or related to trauma. As such, dissections due to blunt trauma, surgical instruments, or those that are catheter-induced are not deemed to be SCAD. Furthermore, contemporary usage of the term SCAD is typically reserved for the nonatherosclerotic variant, and most modern series exclude SCAD due to atherosclerotic coronary artery disease. For the purpose of our review, and because this disease is distinct from atherosclerotic disease, the term SCAD refers to "nonatherosclerotic SCAD" and is the focus of this paper.
EPIDEMIOLOGY
SCAD was previously, incorrectly believed to be very rare and to be frequently associated with pregnancy. Unfortunately, the true incidence and prevalence of SCAD in the general population is unknown due to significant underdiagnosis of this condition. For decades, SCAD diagnosis was plagued by a low clinical index of suspicion of seemingly healthy young women presenting with ACS who had not undergone coronary angiography. At the other extreme, SCAD patients who presented with sudden cardiac death may not have been captured in various databases. In addition, the current "gold standard" for a SCAD diagnosis (i.e., coronary angiography) has major limitations because it does not image the arterial wall, and many clinicians are unfamiliar with nonpathognomonic angiographic variants of SCAD.
Furthermore, intracoronary imaging was infrequently used to aid diagnosis. Therefore, the previous reports of SCAD prevalence on coronary angiography of 0.2% to 1.1% were underestimates of the true prevalence of SCAD (18) (19) (20) . In a recent Japanese series of 326 ACS patients who underwent routine OCT imaging, SCAD was diagnosed in 4% of cases (21) . However, caution should be exercised in using this incidence estimate because 77% of these patients were men, and thus a proportion of these dissections were likely related to atherosclerosis. We suspect that a more accurate estimate of the SCAD prevalence in patients presenting with ACS is 1.7% to 4% on the basis of modern series (13, 21) . In the extreme case of sudden cardiac death, SCAD was reported in 0.5% (8 of 1,647) of cases in an autopsy series (22) , although this prevalence could be an underestimate. SCAD affects women in >90% of cases. In contemporary series that excluded patients with atherosclerotic causes, women accounted for 92% to 95% of the population with SCAD (6, 9, 10, (12) (13) (14) . The reported mean age ranged from 44 to 55 years in contemporary series, reflecting a relatively young to middle-age population (6, 9, 10, (12) (13) (14) (15) . In the Vancouver cohort of 168 patients, 58% were $50 years of age, 62% of affected women were post-menopausal, and the oldest patient was 84 years of age (9) . In another series, the oldest reported patient was 78 years of age (7) . In terms of racial distribution, all races can be affected, although most of those in North America were Caucasians (81% to 83%) (7, 9) , which was similar to the racial distribution among patients who underwent percutaneous coronary intervention (PCI) in British Columbia.
MECHANISM AND PATHOPHYSIOLOGY
The arterial dissection with SCAD can occur within or between any of the 3 layers (intima, media, or adventitia) of the coronary artery wall. Two potential mechanisms for the initiation of arterial wall The presence of true lumen compression by IMH can result in myocardial ischemia and infarction.
Occlusion of the lumen by thrombi in the true or false lumen may also occur, such as at intimal rupture sites. Two large angiographic series and 1 OCT (25 SCAD arteries) series showed lack of thrombus in the arterial lumen (9, 10, 27) . However, 1 small OCT study of 11 patients showed thrombi in the false or true lumen in all cases, but most were insignificant (28).
Thus, it appears that thrombi play a secondary pathophysiologic role compared with IMH as the primary cause of ACS with SCAD.
PREDISPOSING AND PRECIPITATING ETIOLOGIES
The underlying etiology of SCAD appears to be multifactorial. There is often an associated underlying predisposing arteriopathy, which may be compounded by a precipitating stressor, culminating in the phenotypic expression of SCAD ( births, and 8.3% were grand multigravida, with $5
pregnancies (9).
HORMONAL THERAPY. Long-term exposure to exogenous estrogen or progesterone is postulated to cause similar long-term changes in coronary arterial architecture, and it is believed to be an important risk factor for SCAD (7, 9) . In a presented series of 215 SCAD patients, 12.4% were actively on hormone replacement therapy, and these patients had higher recurrent MI (29.2% vs. 6.5%; p ¼ 0.03) on follow-up compared with those not on hormone replacement therapy (45) .
SYSTEMIC INFLAMMATORY DISEASE. Several chronic systemic inflammatory conditions were reported to be potentially associated with SCAD (Table 1) , although most of these were only case reports, and the pathophysiological links were not established.
The prevalence of concomitant systemic inflammatory disease was 8.9% in the 168 patient series. In a smaller series by Alfonso et al. (8), 27 patients diagnosed with isolated SCAD underwent laboratory screening for inflammatory and immunologic markers; however, none were diagnosed with systemic inflammation on screening. This is in keeping with the observation that the incidence of acute inflammation associated with SCAD was very low (<1%) (9) . The link between systemic inflammation and SCAD is suspected to be due to chronic inflammation from vasculitis (46) . 
CLINICAL PRESENTATION
There is a wide spectrum of clinical presentations and severity of SCAD. Almost all patients with SCAD present with ACS and elevation of cardiac enzymes (9, 11, 12, 15) . The proportion who presented with STEMI varied widely in different series, ranging from 24% to 87% (9-15). A small proportion can be complicated with ventricular arrhythmias (3% to 10%)
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Spontaneous Coronary Artery Dissection Review (9-11), cardiogenic shock (<3%) (9,11), or sudden cardiac death (<1%), although this presentation may be underestimated (22) . Overall, w34% of SCAD patients had unstable symptoms (ongoing pain and/or ischemia or stuttering and/or recurrent pain that required medications for pain relief) before arrival at the catheterization laboratory.
There is also a wide variation in elevation of cardiac enzyme levels. In the Vancouver cohort, the median troponin I elevation was 6 mg/l (normal <0.05 mg/l), with a wide interquartile range of 0.7 to 200 mg/l (9) . Interestingly, in the Japanese series, the mean 
Chest pain is the most commonly reported symptom with SCAD presentation (51) . SCAD ¼ spontaneous coronary artery dissection;
However, such descriptions and the National Heart, Lung, and Blood Institute classification for coronary dissections were devised in the pre-stent era for angioplasty-induced dissections. The predominant angiographic appearance of SCAD consists of smooth narrowing of varying severity and length due to IMH.
Thus, a SCAD angiographic classification was described to better characterize the appearance (55) . Using this classification, the most common SCAD angiographic appearance was type 2 in 67.5% of cases (137 of 203), followed by type 1 in 29.1% (59 of 203), and type 3 in 3.4% (7 of 203) (9) . Other investigators have also reported diffuse smooth stenosis to be the most common angiographic manifestation (13, 15, 28) .
These findings highlight the importance of familiarity with the nonpathognomonic variants of SCAD (types 2 and 3) to improve diagnosis. The type 2 variants are associated with very long lengths of narrowing (mean 58 mm) and can be readily identifiable as SCAD after familiarity with this appearance; however, intracoronary imaging or repeat angiography in 4 to 6 weeks should be considered if the diagnosis is uncertain. The type 2B variant may be mistaken as "normal vessel tapering," but there is usually a discernible demarcation from a normal vessel to stenosis. Furthermore, there is usually a corresponding regional wall motion abnormality on ventriculography. The type 3 variant may be significantly underdiagnosed (mean length 22 mm), and may be mistaken for atherosclerotic disease if intracoronary imaging is not performed (27) .
SCAD DISTRIBUTION. Any coronary artery can be affected by SCAD, with the left anterior descending artery being the most commonly involved (34% to 42%) (9, 11, 12) . Overall, the left anterior descending artery and its branches (diagonal or septal) are affected in 45% to 61%, the circumflex and branches (ramus, obtuse marginal) in 15% to 45%, the right coronary artery and branches (acute marginal, posterior descending, posterolateral) in 10% to 39%, and the left main in 0% to 4% of cases (9) (10) (11) (12) (13) 15) . Most dissections affected the mid to distal segments, with <10% affecting the proximal left anterior descending, circumflex, right coronary, or left main arteries (9) . Multiple arteries were dissected in 9% to 19% of cases, and noncontiguous >1 artery dissections occurred in 5% to 10% of cases (9-13,15). The mean stenosis severity was 79%, and the mean length of dissection was 46 mm (9). Thrombolysis In Myocardial Infarction (TIMI) flow grade 0 was observed in 24% to 44% of cases, TIMI flow grade 1 in 5% to 13%, TIMI flow grade 2 in 15% to 26%, and TIMI flow grade 3 in 19% to 55% of cases (9, 12, 15) . However, it may be useful as an alternative to angiography to assess for arterial healing after SCAD of larger proximal-mid arteries. In a small series of 34 patients, 24 patients underwent cardiac CTA at a median of 4 months, and complete healing was observed in 83% (14) .
MANAGEMENT OF SCAD
The optimal management of SCAD remains undeter- A n t i c o a g u l a n t a n d t h r o m b o l y t i c t h e r a p y . The role of anticoagulation for SCAD is controversial and has not been studied. Heparin agents are routinely administered for ACS management in hospital, but the clinical benefit has not been established for SCAD.
There is a potential risk of extending the dissection with anticoagulation, which is balanced by the potential benefit of resolving overlying thrombus and improving true lumen patency. Heparin should likely be discontinued once the SCAD diagnosis is made;
however, this practice remains controversial and lacks supportive data. Thrombolytic therapy should be avoided in SCAD because there have been reports of harm and clinical deterioration due to extension of IMH and dissection (62, 63) . In a retrospective review of 87 SCAD patients who received thrombolysis, 60%
had clinical deterioration that required rescue PCI or coronary artery bypass grafting (CABG) (62) . There are anecdotal reports of successful thrombolysis with SCAD that may be related to lysis of false lumen thrombi (64); however, the bulk of the data suggest harm with thrombolysis for SCAD. Saw et al.
Angiotensin-converting enzyme inhibitor or angiotensinreceptor blocker. These agents are standardly recom- Saw et al.
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16.1%; p ¼ 0.028) (11) .
P C I c h a l l e n g e s . These suboptimal results are a consequence of multiple challenges with PCI in this anatomy ( Table 4) However, long-term results with CABG appears suboptimal, with reported graft patency of 27% in a small series (7), which may be related to spontaneous arterial healing, with subsequent competitive flow causing graft thrombosis. Nevertheless, CABG is an important temporizing strategy, providing coronary blood flow and myocardial perfusion for these critically ill patients in whom PCI is unsuitable.
POST-DISCHARGE RECOMMENDATIONS. At our institution, long-term medical management routinely consists of aspirin and beta-blockers, with the addition of angiotensin-converting enzyme inhibitors and statins as required. Cardiac rehabilitation is also highly encouraged, especially if a dedicated program for became pregnant in a small series was 1 of 7 (14%) (77) .
CARDIOVASCULAR OUTCOMES
The in-hospital outcomes of SCAD patients are reasonably good in contemporary prospective series (Table 3) . Acute in-hospital mortality was <5% in modern series, and in-hospital recurrent MI, need for urgent revascularization in conservatively managed patients, or other MACEs were 5% to 10% (7,9,11).
However, following hospital discharge, a significant proportion of patients can have recurrent chest pains and MACEs. Subacute MACEs were reported in 10% to 20% of patients at 2-year follow-up, with recurrent SCAD occurring in w15% (9). Longer-term recurrent SCAD rates at 4 to 5 years were reported at w27% (10, 15) . Although overall long-term survival is good in this cohort (>95%), long-term MACE rates can be high, and were reported to be 15% to 37% at 5 to 7 years and estimated at w50% at 10 years (7, 9, 11, 15 
